Thymic NK-Cells and Their Potential in Cancer Immunotherapy

Natural killer (NK)-cells are innate immune cells with potent anti -tumor capacity, capable of recognizing target cells without prior exposure. For this reason, NK-cells are recognized as a useful source of cell therapy. Although most NK-cells are derived from the bone marrow (BM), a separate developmental pathway in the thymus also exists, producing so-called thymic NK-cells. Unlike conventional NK-cells, thymic NK (tNK)-cells have a combined capacity for cytokine production and a natural ability to kill tumor cells in the presence of NK-cell receptor stimulatory ligands. Furthermore, tNK-cells are reported to express CD3 subunits intracellularly, without the presence of a rearranged T -cell receptor (TCR). This unique feature may enable harnessing of these cells with a TCR to combine NKand T -cell effector properties in one cell type. The development, phenotype, and function of tNK-cells, and potential as a cell therapy is, however, poorly explored. In this review, we provide an overview of current literature on both murine and human tNK-cells in comparison to conventional BM -derived NK-cells, and discuss the potential applications of this cellular subset in the context of cancer immunotherapy.